{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=etrumadenant", "query": { "intervention": "etrumadenant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=etrumadenant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T17:33:00.995Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04791839", "title": "Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Non-small Cell Carcinoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-08-04", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04791839" }, { "nct_id": "NCT03821246", "title": "Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Prostate Cancer", "Localized Prostate Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Oh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 68, "start_date": "2019-10-30", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 2, "location_summary": "San Francisco, California • St Louis, Missouri", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821246" }, { "nct_id": "NCT04381832", "title": "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant", "Androgen-Resistant Prostatic Neoplasms", "Castration Resistant Prostatic Neoplasms", "Prostatic Cancer, Castration-Resistant" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "SG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 173, "start_date": "2020-07-07", "completion_date": "2024-08-30", "has_results": false, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 17, "location_summary": "Cerritos, California • Encino, California • Orange, California + 14 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04381832" }, { "nct_id": "NCT05335941", "title": "A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Metastatic Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2023-06-13", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05335941" }, { "nct_id": "NCT05886634", "title": "A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dedifferentiated Liposarcoma", "Soft Tissue Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma", "Recurrent Dedifferentiated Liposarcoma", "Unresectable Dedifferentiated Liposarcoma", "Metastatic Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2023-05-23", "completion_date": "2027-05-23", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05886634" }, { "nct_id": "NCT03629756", "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Merkel Cell Carcinoma", "GastroEsophageal Cancer", "Renal Cell Carcinoma", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-07-24", "completion_date": "2021-09-03", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03629756" }, { "nct_id": "NCT05154136", "title": "A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2021-10-20", "completion_date": "2021-12-10", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05154136" }, { "nct_id": "NCT06048484", "title": "Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Stereotactic body radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Modified FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Gulam Manji", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-05-10", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 5, "location_summary": "Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06048484" }, { "nct_id": "NCT04660812", "title": "An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "AB680", "type": "DRUG" }, { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "m-FOLFOX-6 regimen", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2021-05-10", "completion_date": "2025-09-05", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 17, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660812" }, { "nct_id": "NCT05024097", "title": "A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Etrumadenant (AB928)", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Zimberelimab (AB122)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2022-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-11T17:33:00.995Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05024097" } ] }